Covid-19 roundup: BioNTech offers data showing Pfizer-partnered vaccine protects against variant; Novavax attributes responsibility for PhIII delay to OWS
Ugur Sahin and his team at BioNTech have proffered more evidence that their Pfizer-partnered Covid-19 vaccine can protect people from a much-feared variant of SARS-CoV-2.
Colloquially known as the UK variant, the B.1.1.7 lineage triggered alarms because it appeared more transmissible. Among a series of mutations on its spike protein — the key antigen that all frontrunners in the vaccine race targeted — N501Y was of particular concern because it’s located on the receptor-binding site.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.